EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Gelesis Holdings's enterprise value is $54.12 Mil.
Gelesis Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-40.21 Mil. Therefore, Gelesis Holdings's EV-to-EBITDA for today is -1.35.
The historical rank and industry rank for Gelesis Holdings's EV-to-EBITDA or its related term are showing as below:
GLSHQ'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -5.91 Med: -1.74 Max: -1.34
Current: -1.34
During the past 2 years, the highest EV-to-EBITDA of Gelesis Holdings was -1.34. The lowest was -5.91. And the median was -1.74.
GLSHQ's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.55
vs GLSHQ: -1.34
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Gelesis Holdings EV-to-EBITDA Historical Data
The historical data trend for Gelesis Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Gelesis Holdings's EV-to-EBITDA
For the Biotechnology subindustry, Gelesis Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gelesis Holdings's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gelesis Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Gelesis Holdings's EV-to-EBITDA falls into.
Gelesis Holdings's current Enterprise Value is $54.12 Mil.
Gelesis Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-40.21 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Gelesis Holdings's PE Ratio for today is calculated as:
Gelesis Holdings's share price for today is $0.0021.
Gelesis Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.700.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Gelesis Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Gelesis Holdings (Gelesis Holdings) Business Description
Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GLSHQ has been successfully added to your 